status, such as transplant recipients, chemotherapy patients, underweight neonates and those infected by the human immunodefi ciency virus. Signifi cant morbidity and mortality rates have been associated with Candida spp. bloodstream infections [1 -3].
Introduction
Candida infections have progressively emerged as major nosocomial invasive fungal diseases since the late 1980s, mainly arising from an endogenous source, i.e., either digestive or mucocutaneous. Commensalism, followed by colonization, usually precedes dissemination, most frequently in patients with transient or permanent immunocompromised molecular tool for the swift and accurate differentiation of C. albicans [6, 7] isolates.
During a 12-month period (2004) a prospective study addressing fungaemia was conducted at Hospital de S ã o Jo ã o, a large university hospital located in the Northern region of Portugal [1] . The epidemiological data analyzed included, among others, the department of admission, underlying diseases and antimicrobial therapy. Several yeast isolates from blood cultures were collected and studied, as well as fungi recovered from surveillance cultures or from medical indwelling devices. These included isolates from distinct biological sources of the same patient, such as urine and lower respiratory secretions, and from central venous catheters. All episodes of recurrence were investigated [1] .
Our main purpose was to genotype all C. albicans isolates by using a multiplex PCR system with four microsatellite loci. Ultimately, we aimed to determine the genetic relatedness between simultaneous and/or recurrent isolates from the same patient, the source of infection, the route of transmission, as well as the possibility of transmission among distinct patients. Additionally, the susceptibility profi les of all isolates were determined and evaluated with respect to antifungal therapy.
Materials and methods

Patients ' clinical data
Thirty-fi ve C. albicans isolates recovered from the blood and other biological sources were obtained from 12 patients with fungaemia. The data documented included patient gender and age, department and date of admission, concomitant therapy (i.e., immunossuppressors), date and site of fungal isolation, and nosocomial origin of the fungaemia. According to the Centre for Disease Control and Prevention (CDC), nosocomial fungaemia is defi ned as having occurred whenever at least one fungal positive blood culture is obtained within 48 h of the patient ' s hospital admission [8] . Antifungal therapy (prophylactic or therapeutic) and clinical outcome (survival/death) were also documented. Outcomes were evaluated 30 days after the fi rst fungaemia episode, with related deaths being defi ned as those that occurred within 30 days of the fi rst fungal positive blood culture, with no signs of intracerebral or gastrointestinal bleeding or pulmonary embolism. All Candida isolates were frozen at -70 ° C in brain-heart medium with 5% of glycerol (Difco) and subcultured twice on Sabouraud agar (Difco) prior to experimental procedures.
C. albicans genotyping
Yeast strains were grown overnight in Sabouraud broth at 30 ° C. A Zymolyase-based method was used to extract DNA, as previously described [9] . To assess strain relatedness, all isolates were genotyped using a microsatellite multiplex PCR assay with three markers (CAI, CAIII and CAVI) as described by Sampaio et al . [7] and a singleplex amplifi cation reaction assay using the microsatellite marker CEF3, according to procedures described by Bretagne et al . [4] . Following PCR amplifi cation, a 1 -2-μ l aliquot of each sample was added to 15 μ l of formamide containing 0.4 μ l of GeneScan -500 TAMRA size standards (Applied Biosystems). Amplicons were denatured at 95 ° C for 5 min and immediately placed on ice. Denatured samples were resolved by capillary electrophoresis in an ABI Prism 310 genetic analyzer (Applied Biosystems). Determination of allele sizes was automatically performed with GeneScan 3.7 analysis software. The alleles were designated according to the number of repeated units for the CAI [(CAA) 2 CTG(CAA) n ], CAIII [(GAA) n ] and CAVI ((TAAA) n ) markers and by the number of nucleotides for the CEF3 [(TTTC) n (TTC) n ] marker.
Antifungal susceptibility profi le
Antifungal susceptibility testing of all isolates was performed according to the CLSI M27 A3 protocol in RPMI 1640 (Sigma) [10, 11] . Minimal inhibitory concentration (MIC) for fl uconazole, voriconazole, caspofungin and amphotericin B were determined [10, 11] . The yeast strains were classifi ed as susceptible (S), susceptible-dose dependent (S-DD) and resistant ® to azoles according to the breakpoints defi ned by CLSI [10, 11] . Although defi nitive breakpoints have not yet been established for amphotericin B, strains showing MIC Յ 1 μ g/ml were considered susceptible [12] . For caspofungin, strains with an MIC Յ 2 μ g/ml corresponded to S and Ͼ 2 μ g/ml to non-susceptible (NS) [10, 11] . Strains displaying a MIC variation within one dilution were considered as having a similar susceptibility pattern.
Results
The patients ' age ranged from 40 -83 years old and 75% (9/12) were male. Data such as department of admission, date of fi rst isolation and strain origin are presented in Table 1 and Fig. 1 . All patients were iatrogenically immunosuppressed, and 75% died. All fungaemia cases corresponded to episodes of nosocomial infections. The microsatellite genotyping analysis is detailed in Table 1 .
Among the 12 patients, two or more isolates were obtained from blood and from additional body locations. We considered isolates as being highly related when their genotypes differed at only a single locus. In the large majority of patients, blood isolates displayed the same multilocus genotype or a genotype that was highly similar to that of isolates from other body locations. In one single case, patient 10, one isolate from urine exhibited a completely distinct was indicative of strain maintenance regardless of antifungal treatment, rather than re-infection by a distinct strain (Table 1) . Isolates from patients 3, 4 and 5 showed identical or highly similar microsatellite profi les (Table 1) , an interesting fact since these patients had initially been simultaneously admitted in the same intensive care unit (ICU). Isolates from patients 6, 7 and 8 also exhibited identical or highly similar genotypes (Table 1) and were initially admitted to the same ICU, although not concurrently. All isolates from patients 1 and 2, who where in the same ICU in the previous months, displayed the same genotype (Table 1) . Sharing of the same strain among different patients is suggestive of hospital-acquired exogenous nosocomial infection with hospital endemic strains. multilocus genotype from the blood isolate, even though they were collected at the same time. Isolate 9.3 from urine displayed a genotype that differed at two loci compared to the isolates obtained from the respiratory tract or blood isolates. This isolate was moderately related to the other isolates from the same patient but was highly related to isolates from patients 6, 7 and 8. In two patients, 11 and 12, minor genetic differences were detected among blood isolates and those from other body sources. In these patients, the isolates were highly related, suggestive of microevolution.
Consecutive blood isolates from the same patient exhibited the same microsatellite genotype in 5 out of 6 patients. The exception was patient 12 where a highly related isolate was observed between two consecutive blood cultures. This The antifungal therapy timelines are detailed in Fig. 1 . All doses were administered according to the Clinical Practice Guidelines for the management of candidiasis [13] . Four patients (1, 3, 5 and 9) were under antifungal prophylaxis with fl uconazole for 2 or 3 weeks prior to the fi rst fungal isolation. Only patient 1, in which fl uconazole therapy was replaced by amphotericin B, had a favorable outcome. Two patients (patient 3 and 6), with end-stage neoplasic diseases, were infected with fl uconazole-susceptible strains and died due to fungaemia according to their medical records. In patients 3, 4 and 5 who were infected by the same strain, MIC increases were observed. Isolates from patients 4 and 5 that were collected several months after isolates from patient 3 were resistant to azoles (Table 1 and Fig. 1) . Similarly, we observed azole cross-resistance in isolates from patient 8 that were collected several months after isolates from patients 6 and 7. All of these isolates had identical genotypes and probably represented the same strain (Table 1 and Fig. 1) .
All of the isolates analyzed showed low MIC values to amphotericin B and caspofungin ( Յ 1 μ g/ml) ( Table 1) .
Discussion
Nosocomial infections represent an important source of morbidity and mortality in hospital settings [14] . An understanding of pathogen distribution and relatedness is critical for both the epidemiological surveillance of healthcare related infections and for the development of rational pathogen control policies [15] . Pathogen typing allows for the determination of genetically-and epidemiologicallyrelated isolates. The development and implementation of new DNA-based technologies and molecular analyses over the last 3 decades have led to considerable advances in microbial typing approaches [16 -19] . The identifi cation of a pathogen ' s origin, e.g., endogenous versus exogenous, and the characterization of consecutive infections by the same organism as relapse or re-infection are critical [19] . Our group has previously developed a microsatellite multiplex PCR strategy with high discriminatory power for typing Candida albicans [7] . This methodology was found to effi ciently discriminate C. albicans strains, as well as C. glabrata , C. parapsilosis and C. tropicalis [17, 20, 21] . Maintenance and infection by the same strain may indicate that the therapeutic regimen was unsuccessful and that alternative therapies might be required. The results obtained here for successive blood isolates from the same patient suggest the failure of antifungal therapy in these cases. Moreover, fungal strains may invade the host from different body sites, and microevolution, due to strand slippage during DNA replication in the microsatellite region or loss of heterozygosity (LOH), may represent an adaptive fungal response to new environments [7, 18] . We detected microevolution events in 3 patients (9, 11 and 12) . C. albicans colonization and/or infection of different body sites may represent a predisposing condition or an initial step towards subsequent development of fungaemia [3, 22] . All the fungaemia cases considered in this study were of nosocomial origin, according to the accepted defi nition [8] . Our results clearly demonstrate that isolates displaying the same or highly similar genotypes were obtained from patients who shared the same hospital department of admission which clearly suggests hospital-acquired infections. These observations indicate that the safety measures used between patients most probably failed and that incidents of cross-infection were likely to have occurred.
In our study, fungaemia relapses were frequent, appeared to be caused by the same strain, and were invariably associated to a poor therapeutic outcome. The extension of crossresistance to azoles detected among fungaemia patients may challenge the large empiric use of fl uconazole and how it can lead to the development of dramatic resistance. We observed induction of azoles resistance in two groups of patients (patients 3, 4 and 5 and patients 6, 7 and 8) and the increase in MIC values, over time, in similar strains from different patients suggests that the strains were endemic to the hospital environment for at least several months. This exemplifi es the risk of selecting for strains with increased antifungal resistance in the hospital environment.
The molecular identity of fungal isolates represents a key feature for comprehensible therapeutic strategies in a near future; indeed, analysis of dominant genotypes in different geographical regions, distinct clinical samples and separate underlying diseases is now a possibility. Molecular approaches are now available, allowing detailed comparisons between C. albicans clinical strains and providing a clear defi nition of their genetic relatedness.
